{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:48:24Z","timestamp":1791478104097,"version":"4.3.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1007\/s00415-025-13485-3","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:57:45Z","timestamp":1761746265000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Efgartigimod-rituximab sequential therapy in Anti-NMDAR encephalitis: real-world evidence for a novel salvage-maintenance strategy"],"prefix":"10.1007","volume":"272","author":[{"given":"Yao","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jihong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyang","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinqin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9988-1606","authenticated-orcid":false,"given":"Donglin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"13485_CR1","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/S1474-4422(19)30244-3","volume":"18","author":"J Dalmau","year":"2019","unstructured":"Dalmau J, Armangue T, Planaguma J, Radosevic M, Mannara F, Leypoldt F, Geis C, Lancaster E, Titulaer MJ, Rosenfeld MR, Graus F (2019) An update on anti-NMDA receptor encephalitis for neurologists and psychiatrists: mechanisms and models. Lancet Neurol 18:1045\u20131057. https:\/\/doi.org\/10.1016\/S1474-4422(19)30244-3","journal-title":"Lancet Neurol"},{"key":"13485_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.861988","volume":"13","author":"F Liu","year":"2022","unstructured":"Liu F, Zhang B, Huang T, Wang B, Wang C, Hao M, Guo S (2022) Influential factors, treatment and prognosis of autoimmune encephalitis patients with poor response to short-term first-line treatment. Front Neurol 13:861988. https:\/\/doi.org\/10.3389\/fneur.2022.861988","journal-title":"Front Neurol"},{"key":"13485_CR3","doi-asserted-by":"publisher","first-page":"369","DOI":"10.3988\/jcn.2019.15.3.369","volume":"15","author":"X Zhang","year":"2019","unstructured":"Zhang X, Wang C, Zhu W, Wang B, Liang H, Guo S (2019) Factors affecting the response to first-line treatments in patients with anti-N-methyl-D-aspartate receptor encephalitis. J Clin Neurol 15:369\u2013375. https:\/\/doi.org\/10.3988\/jcn.2019.15.3.369","journal-title":"J Clin Neurol"},{"key":"13485_CR4","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/jca.21938","volume":"36","author":"Y Yang","year":"2021","unstructured":"Yang Y, Zhang B, Li M, Li J (2021) Successful treatment with immunoadsorption therapy in four patients with severe and refractory anti-N-methyl-D-aspartate receptor encephalitis. J Clin Apher 36:886\u2013892. https:\/\/doi.org\/10.1002\/jca.21938","journal-title":"J Clin Apher"},{"key":"13485_CR5","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/acn3.51313","volume":"8","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Huang HJ, Chen WB, Liu G, Liu F, Su YY (2021) Clinical efficacy of plasma exchange in patients with autoimmune encephalitis. Ann Clin Transl Neurol 8:763\u2013773. https:\/\/doi.org\/10.1002\/acn3.51313","journal-title":"Ann Clin Transl Neurol"},{"key":"13485_CR6","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000633","volume":"7","author":"X Xu","year":"2020","unstructured":"Xu X, Lu Q, Huang Y, Fan S, Zhou L, Yuan J, Yang X, Ren H, Sun D, Dai Y, Zhu H, Jiang Y, Zhu Y, Peng B, Cui L, Guan H (2020) Anti-NMDAR encephalitis: a single-center, longitudinal study in China. Neurol Neuroimmunol Neuroinflamm 7:e633. https:\/\/doi.org\/10.1212\/NXI.0000000000000633","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13485_CR7","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","volume":"71","author":"F Fazekas","year":"2008","unstructured":"Fazekas F, Lublin FD, Li D, Freedman MS, Hartung HP, Rieckmann P, Sorensen PS, Maas-Enriquez M, Sommerauer B, Hanna K, P.S. Group, U.M.M.R. Group (2008) Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial. Neurology 71:265\u201371. https:\/\/doi.org\/10.1212\/01.wnl.0000318281.98220.6f","journal-title":"Neurology"},{"key":"13485_CR8","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.ejpn.2011.07.005","volume":"16","author":"P Kashyape","year":"2012","unstructured":"Kashyape P, Taylor E, Ng J, Krishnakumar D, Kirkham F, Whitney A (2012) Successful treatment of two paediatric cases of anti-NMDA receptor encephalitis with cyclophosphamide: the need for early aggressive immunotherapy in tumour negative paediatric patients. Eur J Paediatr Neurol 16:74\u201378. https:\/\/doi.org\/10.1016\/j.ejpn.2011.07.005","journal-title":"Eur J Paediatr Neurol"},{"key":"13485_CR9","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2022-249991","volume":"15","author":"AFP Barbadillo","year":"2022","unstructured":"Barbadillo AFP, Quimpo RAS, Sanchez-Gan B (2022) Case of anti-NMDA receptor encephalitis in a female adolescent with favourable response to second-line treatment with cyclophosphamide. BMJ Case Rep 15:e249991. https:\/\/doi.org\/10.1136\/bcr-2022-249991","journal-title":"BMJ Case Rep"},{"issue":"Suppl 2","key":"13485_CR10","doi-asserted-by":"publisher","first-page":"S171","DOI":"10.1007\/s10072-009-0145-4","volume":"30","author":"L Rinaldi","year":"2009","unstructured":"Rinaldi L, Perini P, Calabrese M, Gallo P (2009) Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks. Neurol Sci 30(Suppl 2):S171\u2013S173. https:\/\/doi.org\/10.1007\/s10072-009-0145-4","journal-title":"Neurol Sci"},{"key":"13485_CR11","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1007\/s10072-025-08228-1","volume":"46","author":"H Wu","year":"2025","unstructured":"Wu H, Xu F, Chen Y, Ding S, Li W, Li Q, Chen N, Tang L (2025) Low-dose rituximab for the treatment of anti-NMDAR encephalitis in children: a case series study. Neurol Sci 46:3813\u20133818. https:\/\/doi.org\/10.1007\/s10072-025-08228-1","journal-title":"Neurol Sci"},{"key":"13485_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2025.e41747","volume":"11","author":"LM Zhang","year":"2025","unstructured":"Zhang LM, Xing XL, Zhang BR, Zhang QJ, Zhu YL, Gao SJ, Liu MW (2025) Efficacy of rituximab as second-line therapy for autoimmune encephalitis: a systematic review and meta-analysis. Heliyon 11:e41747. https:\/\/doi.org\/10.1016\/j.heliyon.2025.e41747","journal-title":"Heliyon"},{"key":"13485_CR13","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2024.09.001","volume":"161","author":"D Zhang","year":"2024","unstructured":"Zhang D, Li B, Li J, Tong L, Yang L (2024) Efficacy and safety of rituximab treatment for anti-N-methyl-d-aspartate receptor encephalitis without tumor in children. Pediatr Neurol 161:85\u201390. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2024.09.001","journal-title":"Pediatr Neurol"},{"key":"13485_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1136\/practneurol-2018-001899","volume":"19","author":"DH Whittam","year":"2019","unstructured":"Whittam DH, Tallantyre EC, Jolles S, Huda S, Moots RJ, Kim HJ, Robertson NP, Cree BAC, Jacob A (2019) Rituximab in neurological disease: principles, evidence and practice. Pract Neurol 19:5\u201320. https:\/\/doi.org\/10.1136\/practneurol-2018-001899","journal-title":"Pract Neurol"},{"key":"13485_CR15","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","volume":"27","author":"MB Regazzi","year":"2005","unstructured":"Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, Zaja F, Montagna M, Morra E, Lazzarino M (2005) Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit 27:785\u2013792. https:\/\/doi.org\/10.1097\/01.ftd.0000184162.60197.c1","journal-title":"Ther Drug Monit"},{"key":"13485_CR16","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1002\/ana.21363","volume":"63","author":"A Bar-Or","year":"2008","unstructured":"Bar-Or A, Calabresi PA, Arnold D, Markowitz C, Shafer S, Kasper LH, Waubant E, Gazda S, Fox RJ, Panzara M, Sarkar N, Agarwal S, Smith CH (2008) Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 63:395\u2013400. https:\/\/doi.org\/10.1002\/ana.21363","journal-title":"Ann Neurol"},{"key":"13485_CR17","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000042436","volume":"104","author":"L Shen","year":"2025","unstructured":"Shen L, Liu H, Liu X, Zhang L, Wang J, Yang N, Yan N (2025) An adolescent patient with anti-N-methyl-D-aspartate receptor encephalitis with motor aphasia as the first symptom and complicated by peripheral nerve damage: a case report and literature review. Medicine (Baltimore) 104:e42436. https:\/\/doi.org\/10.1097\/MD.0000000000042436","journal-title":"Medicine (Baltimore)"},{"key":"13485_CR18","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12883-025-04034-6","volume":"25","author":"H Huang","year":"2025","unstructured":"Huang H, Wei Y, Qin H, Han G, Li J (2025) Successful treatment with efgartigimod as an add-on therapy for acute attack of anti-NMDA receptor encephalitis: a case report. BMC Neurol 25:31. https:\/\/doi.org\/10.1186\/s12883-025-04034-6","journal-title":"BMC Neurol"},{"key":"13485_CR19","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s10072-024-07843-8","volume":"46","author":"J Xu","year":"2025","unstructured":"Xu J, Guo Z, Zhao J, Chen Y, Liu Z, Wu Y (2025) Efgartigimod treatment for therapy-refractory autoimmune encephalitis with coexistent NMDAR and LGI1 antibodies: a case report and literature review. Neurol Sci 46:1995\u20132005. https:\/\/doi.org\/10.1007\/s10072-024-07843-8","journal-title":"Neurol Sci"},{"key":"13485_CR20","doi-asserted-by":"publisher","first-page":"1444288","DOI":"10.3389\/fimmu.2024.1444288","volume":"15","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Yang W, Qian Y, Zhang Y, Zhao H, Shu M, Li Q, Li Y, Ding Y, Shi S, Liu Y, Cheng X, Niu Q (2024) Case report: rapid symptom relief in autoimmune encephalitis with efgartigimod: a three-patient case series. Front Immunol 15:1444288. https:\/\/doi.org\/10.3389\/fimmu.2024.1444288","journal-title":"Front Immunol"},{"key":"13485_CR21","doi-asserted-by":"publisher","first-page":"e2661","DOI":"10.1212\/WNL.0000000000007600","volume":"92","author":"JF Howard Jr","year":"2019","unstructured":"Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido F, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren J, Efgartigimod MGSG (2019) Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis. Neurology 92:e2661\u2013e2673. https:\/\/doi.org\/10.1212\/WNL.0000000000007600","journal-title":"Neurology"},{"key":"13485_CR22","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ejpn.2018.09.008","volume":"23","author":"M Nosadini","year":"2019","unstructured":"Nosadini M, Mohammad SS, Toldo I, Sartori S, Dale RC (2019) Mycophenolate mofetil, azathioprine and methotrexate usage in paediatric anti-NMDAR encephalitis: a systematic literature review. Eur J Paediatr Neurol 23:7\u201318. https:\/\/doi.org\/10.1016\/j.ejpn.2018.09.008","journal-title":"Eur J Paediatr Neurol"},{"key":"13485_CR23","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1136\/jnnp-2024-335400","volume":"96","author":"X Gong","year":"2025","unstructured":"Gong X, Liu Y, Ma Y, Yan B, An D, Guo Y, Liu X, Li X, Cai L, Deng X, Zhou D, Li JM, Hong Z (2025) Long-term maintenance of mycophenolate mofetil in anti-NMDA receptor encephalitis (LEARN): a multicentre, open-label, blinded-endpoint, randomised controlled trial. J Neurol Neurosurg Psychiatry 96:998\u20131007. https:\/\/doi.org\/10.1136\/jnnp-2024-335400","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13485_CR24","doi-asserted-by":"publisher","first-page":"200395","DOI":"10.1212\/NXI.0000000000200395","volume":"12","author":"N Seery","year":"2025","unstructured":"Seery N, Wesselingh R, Beech P, McLaughlin L, Rushen T, Halliday AJ, Ter Horst L, Griffith SP, Forcadela M, Tan TH, Kazzi C, Nesbitt C, Broadley J, Buzzard K, Duncan A, D\u2019Souza WJ, Tran Y, Van Der Walt A, Skinner G, Taylor BV, Swayne A, Brodtmann A, Gillis D, Butler EG, Kalincik T, Seneviratne UK, Macdonell RA, Blum S, Ramanathan S, Malpas CB, Reddel SW, Hardy TA, O\u2019Brien TJ, Sanfilippo PG, Butzkueven H, Monif M, C. Australian Autoimmune Encephalitis (2025) Rituximab use for relapse prevention in anti-NMDAR antibody-mediated encephalitis: a multicenter cohort study. Neurol Neuroimmunol Neuroinflamm 12:200395. https:\/\/doi.org\/10.1212\/NXI.0000000000200395","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13485_CR25","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1001\/jamaneurol.2021.3188","volume":"78","author":"M Nosadini","year":"2021","unstructured":"Nosadini M, Eyre M, Molteni E, Thomas T, Irani SR, Dalmau J, Dale RC, Lim M, N.A.E.C.G. International, Anlar B, Armangue T, Benseler S, Cellucci T, Deiva K, Gallentine W, Gombolay G, Gorman MP, Hacohen Y, Jiang Y, Lim BC, Muscal E, Ndondo A, Neuteboom R, Rostasy K, Sakuma H, Sartori S, Sharma S, Tenembaum SN, Van Mater HA, Wells E, Wickstrom R, Yeshokumar AK (2021) Use and safety of immunotherapeutic management of N-methyl-d-aspartate receptor antibody encephalitis: a meta-analysis. JAMA Neurol 78:1333\u20131344. https:\/\/doi.org\/10.1001\/jamaneurol.2021.3188","journal-title":"JAMA Neurol"},{"key":"13485_CR26","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200421","volume":"12","author":"NL Ciano-Petersen","year":"2025","unstructured":"Ciano-Petersen NL, Villagran-Garcia M, Muniz-Castrillo S, Farina A, Vogrig A, Goncalves D, Nicole F, Rogemond V, Picard G, Aubart M, Psimaras D, Oliver B, Serrano-Castro PJ, Joubert B, Honnorat J (2025) Relapses in anti-NMDAR encephalitis: clinical characterization and predictive features. Neurol Neuroimmunol Neuroinflamm 12:e200421. https:\/\/doi.org\/10.1212\/NXI.0000000000200421","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"13485_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","volume":"10","author":"J Dalmau","year":"2011","unstructured":"Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol 10:63\u201374. https:\/\/doi.org\/10.1016\/S1474-4422(10)70253-2","journal-title":"Lancet Neurol"},{"key":"13485_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.606923","volume":"11","author":"X Dou","year":"2020","unstructured":"Dou X, Li D, Wu Y, Wang Z, Yang L, Ma N, Wang D, Li X (2020) Efficacy and safety of Rituximab in Chinese children with refractory anti-NMDAR encephalitis. Front Neurol 11:606923. https:\/\/doi.org\/10.3389\/fneur.2020.606923","journal-title":"Front Neurol"},{"key":"13485_CR29","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","volume":"12","author":"MJ Titulaer","year":"2013","unstructured":"Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aguilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol 12:157\u2013165. https:\/\/doi.org\/10.1016\/S1474-4422(12)70310-1","journal-title":"Lancet Neurol"},{"key":"13485_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1111\/ene.15214","volume":"29","author":"X Gong","year":"2022","unstructured":"Gong X, Luo R, Liu J, Guo K, Li A, Liu X, Liu Y, Zhou D, Hong Z (2022) Efficacy and tolerability of intravenous immunoglobulin versus intravenous methylprednisolone treatment in anti-N-methyl-d-aspartate receptor encephalitis. Eur J Neurol 29:1117\u20131127. https:\/\/doi.org\/10.1111\/ene.15214","journal-title":"Eur J Neurol"},{"key":"13485_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.jneuroim.2019.02.008","volume":"330","author":"B Deng","year":"2019","unstructured":"Deng B, Yu H, Liu X, Yu X, Zhang X, Li X, Yang W, Dong S, Qiu Y, Chen X (2019) Reduced dosage rituximab in the treatment of anti-N-methyl-d-aspartate receptor encephalitis: an observation study in Chinese patients. J Neuroimmunol 330:81\u201386. https:\/\/doi.org\/10.1016\/j.jneuroim.2019.02.008","journal-title":"J Neuroimmunol"},{"key":"13485_CR32","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/S1474-4422(13)70282-5","volume":"13","author":"N Gresa-Arribas","year":"2014","unstructured":"Gresa-Arribas N, Titulaer MJ, Torrents A, Aguilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J (2014) Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13:167\u2013177. https:\/\/doi.org\/10.1016\/S1474-4422(13)70282-5","journal-title":"Lancet Neurol"},{"key":"13485_CR33","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1007\/s00415-019-09180-9","volume":"266","author":"V Shaygannejad","year":"2019","unstructured":"Shaygannejad V, Fayyazi E, Badihian S, Mirmosayyeb O, Manouchehri N, Ashtari F, Asgari N (2019) Long-term tolerability, safety and efficacy of rituximab in neuromyelitis optica spectrum disorder: a prospective study. J Neurol 266:642\u2013650. https:\/\/doi.org\/10.1007\/s00415-019-09180-9","journal-title":"J Neurol"},{"key":"13485_CR34","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00415-016-8183-3","volume":"263","author":"PJ Jongen","year":"2016","unstructured":"Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, Sinnige LG, Verhagen WI, Visser LH, van der Kruijk R, Verheul F, Boringa J, Heerings M, Gladdines W, Lonnqvist F, Gaillard P (2016) Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol 263:1641\u20131651. https:\/\/doi.org\/10.1007\/s00415-016-8183-3","journal-title":"J Neurol"},{"key":"13485_CR35","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1007\/s00415-018-8948-y","volume":"265","author":"GGA van Lieverloo","year":"2018","unstructured":"van Lieverloo GGA, Peric S, Doneddu PE, Gallia F, Nikolic A, Wieske L, Verhamme C, van Schaik IN, Nobile-Orazio E, Basta I, Eftimov F (2018) Corticosteroids in chronic inflammatory demyelinating polyneuropathy: a retrospective, multicentre study, comparing efficacy and safety of daily prednisolone, pulsed dexamethasone, and pulsed intravenous methylprednisolone. J Neurol 265:2052\u20132059. https:\/\/doi.org\/10.1007\/s00415-018-8948-y","journal-title":"J Neurol"},{"key":"13485_CR36","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1111\/epi.17327","volume":"63","author":"A Halliday","year":"2022","unstructured":"Halliday A, Duncan A, Cheung M, Boston RC, Apiwattanakul M, Camacho X, Bowden S, D\u2019Souza W (2022) Second-line immunotherapy and functional outcomes in autoimmune encephalitis: a systematic review and individual patient data meta-analysis. Epilepsia 63:2214\u20132224. https:\/\/doi.org\/10.1111\/epi.17327","journal-title":"Epilepsia"},{"key":"13485_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2021.577479","volume":"352","author":"X Li","year":"2021","unstructured":"Li X, Hou C, Wu WL, Liang H, Zheng K, Zhang Y, Zeng Y, Chen L, Zhu H, Tian Y, Gao Y, Peng B, Yang S, Wang X, Ning S, Liao Y, Lin H, Chen WX (2021) Pediatric anti-N-methyl-d-aspartate receptor encephalitis in southern China: analysis of 111 cases. J Neuroimmunol 352:577479. https:\/\/doi.org\/10.1016\/j.jneuroim.2021.577479","journal-title":"J Neuroimmunol"},{"key":"13485_CR38","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","volume":"7","author":"J Dalmau","year":"2008","unstructured":"Dalmau J, Gleichman AJ, Hughes EG, Rossi JE, Peng X, Lai M, Dessain SK, Rosenfeld MR, Balice-Gordon R, Lynch DR (2008) Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol 7:1091\u20131098. https:\/\/doi.org\/10.1016\/S1474-4422(08)70224-2","journal-title":"Lancet Neurol"},{"key":"13485_CR39","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1007\/s12028-021-01283-4","volume":"36","author":"X Wang","year":"2022","unstructured":"Wang X, Wan J, Wei Z, Song C, Kang X, Du F, Jiang W, Yang F (2022) Status epilepticus in patients with anti-NMDAR encephalitis requiring intensive care: a follow-up study. Neurocrit Care 36:192\u2013201. https:\/\/doi.org\/10.1007\/s12028-021-01283-4","journal-title":"Neurocrit Care"},{"key":"13485_CR40","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1684\/epd.2020.1218","volume":"22","author":"JS Gofshteyn","year":"2020","unstructured":"Gofshteyn JS, Yeshokumar AK, Jette N, Thakur KT, Luche N, Yozawitz E, Varnado S, Klenofsky B, Tuohy MC, Ankam J, Torres S, Hesdorffer D, Nelson A, Wolf S, McGoldrick P, Yan H, Basma N, Grinspan Z (2020) Clinical and electrographic features of persistent seizures and status epilepticus associated with anti-NMDA receptor encephalitis (anti-NMDARE). Epileptic Disord 22:739\u2013751. https:\/\/doi.org\/10.1684\/epd.2020.1218","journal-title":"Epileptic Disord"},{"key":"13485_CR41","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.3389\/fneur.2018.01136","volume":"9","author":"Q Huang","year":"2018","unstructured":"Huang Q, Ma M, Wei X, Liao Y, Qi H, Wu Y, Wu Y (2018) Characteristics of seizure and antiepileptic drug utilization in outpatients with autoimmune encephalitis. Front Neurol 9:1136. https:\/\/doi.org\/10.3389\/fneur.2018.01136","journal-title":"Front Neurol"},{"key":"13485_CR42","doi-asserted-by":"publisher","first-page":"4307","DOI":"10.1007\/s10072-023-07018-x","volume":"44","author":"GG Bandeira","year":"2023","unstructured":"Bandeira GG, Barreto Lima P, Araujo D, Pinheiro MSN, Albuquerque Mota L, Simao RM, de Carvalho FMO, Vazquez FD, de Vasconcelos Gama VC, de Queiroz DC, da Fonseca Lira MZR, de Oliveira Junior PH, Guimaraes Junior FA, Caminha GC, de Figueiredo Santos C, Sobreira-Neto MA, Braga-Neto P, Silva GD, Nobrega PR (2023) Controversies in immunotherapy for anti-NMDA receptor encephalitis: a scoping review with a proposal of operational definitions. Neurol Sci 44:4307\u20134312. https:\/\/doi.org\/10.1007\/s10072-023-07018-x","journal-title":"Neurol Sci"},{"key":"13485_CR43","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1007\/s13311-020-00921-7","volume":"18","author":"WJ Lee","year":"2021","unstructured":"Lee WJ, Lee ST, Shin YW, Lee HS, Shin HR, Kim DY, Kim S, Lim JA, Moon J, Park KI, Kim HS, Chu K, Lee SK (2021) Teratoma removal, steroid, IVIG, rituximab and tocilizumab (T-SIRT) in anti-NMDAR encephalitis. Neurotherapeutics 18:474\u2013487. https:\/\/doi.org\/10.1007\/s13311-020-00921-7","journal-title":"Neurotherapeutics"},{"key":"13485_CR44","doi-asserted-by":"publisher","unstructured":"do Valle DA, Galeazzi JSP, Machado MR, Dos Santos V, da Silva AF, Lohr Junior, A Santos M, Scola (2019) Clinical variability of children with anti-N-methyl-D-aspartate receptor encephalitis in southern Brazil: a cases series and review of the literature. Neurol Sci 40: 351\u20136. https:\/\/doi.org\/10.1007\/s10072-018-3648-z","DOI":"10.1007\/s10072-018-3648-z"},{"key":"13485_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.858450","volume":"13","author":"Z Chen","year":"2022","unstructured":"Chen Z, Zhang Y, Wu X, Huang H, Chen W, Su Y (2022) Characteristics and outcomes of paroxysmal sympathetic hyperactivity in anti-NMDAR encephalitis. Front Immunol 13:858450. https:\/\/doi.org\/10.3389\/fimmu.2022.858450","journal-title":"Front Immunol"},{"key":"13485_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2020.577399","volume":"349","author":"M Yamakawa","year":"2020","unstructured":"Yamakawa M, Mukaino A, Kimura A, Nagasako Y, Kitazaki Y, Maeda Y, Higuchi O, Takamatsu K, Watari M, Yoshikura N, Ikawa M, Sugimoto I, Sakurai Y, Matsuo H, Ando Y, Shimohata T, Nakane S (2020) Antibodies to the alpha3 subunit of the ganglionic-type nicotinic acetylcholine receptors in patients with autoimmune encephalitis. J Neuroimmunol 349:577399. https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577399","journal-title":"J Neuroimmunol"},{"key":"13485_CR47","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1177\/1550059419868919","volume":"51","author":"N Lin","year":"2020","unstructured":"Lin N, Huang Y, Jin L, Lu Q, Liu Q, Zhou X, Guan H (2020) Electroencephalogram and clinical characteristics and correlations in patients with anti-N-methyl-d-aspartate receptor encephalitis. Clin EEG Neurosci 51:51\u201360. https:\/\/doi.org\/10.1177\/1550059419868919","journal-title":"Clin EEG Neurosci"},{"key":"13485_CR48","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.686521","volume":"12","author":"N Nathoo","year":"2021","unstructured":"Nathoo N, Anderson D, Jirsch J (2021) Extreme delta brush in anti-NMDAR encephalitis correlates with poor functional outcome and death. Front Neurol 12:686521. https:\/\/doi.org\/10.3389\/fneur.2021.686521","journal-title":"Front Neurol"},{"key":"13485_CR49","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.832634","volume":"13","author":"J Feng","year":"2022","unstructured":"Feng J, Yang M, Cui D, Huang Z, Ji T, Lian Y (2022) Recurrence of anti-N-methyl-D-aspartate receptor encephalitis: a cohort study in central China. Front Neurol 13:832634. https:\/\/doi.org\/10.3389\/fneur.2022.832634","journal-title":"Front Neurol"},{"key":"13485_CR50","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1177\/02841851221091443","volume":"64","author":"S Piao","year":"2023","unstructured":"Piao S, Bao Y, Yang L, Zhang Y, Hu B, Li H, Geng D, Li Y (2023) Brain MRI features of anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis secondary to central nervous system infection in adult patients. Acta Radiol 64:760\u2013768. https:\/\/doi.org\/10.1177\/02841851221091443","journal-title":"Acta Radiol"},{"key":"13485_CR51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.jneuroim.2013.09.017","volume":"265","author":"Y Hachiya","year":"2013","unstructured":"Hachiya Y, Uruha A, Kasai-Yoshida E, Shimoda K, Satoh-Shirai I, Kumada S, Kurihara E, Suzuki K, Ohba A, Hamano S, Sakuma H (2013) Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol 265:128\u2013130. https:\/\/doi.org\/10.1016\/j.jneuroim.2013.09.017","journal-title":"J Neuroimmunol"},{"key":"13485_CR52","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1212\/WNL.0000000000002635","volume":"86","author":"WJ Lee","year":"2016","unstructured":"Lee WJ, Lee ST, Byun JI, Sunwoo JS, Kim TJ, Lim JA, Moon J, Lee HS, Shin YW, Lee KJ, Kim S, Jung KH, Jung KY, Chu K, Lee SK (2016) Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology 86:1683\u20131691. https:\/\/doi.org\/10.1212\/WNL.0000000000002635","journal-title":"Neurology"},{"key":"13485_CR53","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1111\/ane.13291","volume":"142","author":"G Nepal","year":"2020","unstructured":"Nepal G, Shing YK, Yadav JK, Rehrig JH, Ojha R, Huang DY, Gajurel BP (2020) Efficacy and safety of rituximab in autoimmune encephalitis: a meta-analysis. Acta Neurol Scand 142:449\u2013459. https:\/\/doi.org\/10.1111\/ane.13291","journal-title":"Acta Neurol Scand"},{"key":"13485_CR54","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jns.2017.04.007","volume":"377","author":"BJ Wang","year":"2017","unstructured":"Wang BJ, Wang CJ, Zeng ZL, Yang Y, Guo SG (2017) Lower dosages of rituximab used successfully in the treatment of anti-NMDA receptor encephalitis without tumour. J Neurol Sci 377:127\u2013132. https:\/\/doi.org\/10.1016\/j.jns.2017.04.007","journal-title":"J Neurol Sci"},{"key":"13485_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.crwh.2024.e00612","volume":"42","author":"G Jarmoc","year":"2024","unstructured":"Jarmoc G, Smith C, Finnerty E, Noel NL, Marks A (2024) Anti-NMDA encephalitis secondary to an ovarian teratoma presenting as altered mental status in a 32-year-old woman: a case report. Case Rep Womens Health 42:e00612. https:\/\/doi.org\/10.1016\/j.crwh.2024.e00612","journal-title":"Case Rep Womens Health"},{"key":"13485_CR56","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2024-263945","volume":"18","author":"E Polunosika","year":"2025","unstructured":"Polunosika E, Pastare D, Karelis G, Vasylovska V (2025) Development of anti-NMDA receptor encephalitis in a patient with multiple sclerosis. BMJ Case Rep 18:e263945. https:\/\/doi.org\/10.1136\/bcr-2024-263945","journal-title":"BMJ Case Rep"},{"key":"13485_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jocn.2025.111114","volume":"135","author":"G Yan","year":"2025","unstructured":"Yan G, Tian DC, Zhang X, Wang H (2025) Clinical and imaging features and treatment response of anti-NMDAR encephalitis combined with MOGAD. J Clin Neurosci 135:111114. https:\/\/doi.org\/10.1016\/j.jocn.2025.111114","journal-title":"J Clin Neurosci"},{"key":"13485_CR58","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/pathogens12060817","volume":"12","author":"Y Zhou","year":"2023","unstructured":"Zhou Y, Jiang S (2023) Roles of FcRn in antigen-presenting cells during autoimmunity and a clinical evaluation of Efgartigimod as an FcRn blocker. Pathogens 12:817. https:\/\/doi.org\/10.3390\/pathogens12060817","journal-title":"Pathogens"},{"key":"13485_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123597","volume":"371","author":"J Liu","year":"2025","unstructured":"Liu J, Li M, Liu J, Zheng D, Zhou Y, Li Y, Chen X, Lin Y, Yang L, Xu X, Jiang Y, Peng F (2025) Multicenter experience with Efgartigimod in the treatment of anti-NMDAR encephalitis compared with IVIG and SPA-IA during acute attacks. Life Sci 371:123597. https:\/\/doi.org\/10.1016\/j.lfs.2025.123597","journal-title":"Life Sci"},{"key":"13485_CR60","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.ijpharm.2012.06.063","volume":"436","author":"M Paul","year":"2012","unstructured":"Paul M, Vieillard V, Jaccoulet E, Astier A (2012) Long-term stability of diluted solutions of the monoclonal antibody rituximab. Int J Pharm 436:282\u2013290. https:\/\/doi.org\/10.1016\/j.ijpharm.2012.06.063","journal-title":"Int J Pharm"},{"key":"13485_CR61","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/art.21778","volume":"54","author":"P Emery","year":"2006","unstructured":"Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, Racewicz AJ, van Vollenhoven RF, Li NF, Agarwal S, Hessey EW, Shaw TM, D.S. Group (2006) The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 54:1390\u20131400. https:\/\/doi.org\/10.1002\/art.21778","journal-title":"Arthritis Rheum"},{"key":"13485_CR62","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1136\/ard.2009.119933","volume":"69","author":"P Emery","year":"2010","unstructured":"Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, Latinis K, Abud-Mendoza C, Szczepanski LJ, Roschmann RA, Chen A, Armstrong GK, Douglass W, Tyrrell H (2010) Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab\u2019s Efficacy in MTX iNadequate rEsponders (SERENE)). Ann Rheum Dis 69:1629\u20131635. https:\/\/doi.org\/10.1136\/ard.2009.119933","journal-title":"Ann Rheum Dis"},{"key":"13485_CR63","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1093\/rheumatology\/keq116","volume":"49","author":"A Rubbert-Roth","year":"2010","unstructured":"Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, Collinson N, Shaw TM, Investigators MT (2010) Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR). Rheumatology (Oxford) 49:1683\u20131693. https:\/\/doi.org\/10.1093\/rheumatology\/keq116","journal-title":"Rheumatology (Oxford)"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13485-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13485-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,14]],"date-time":"2025-11-14T14:01:15Z","timestamp":1763128875000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13485-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["13485"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13485-3","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"5 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"739"}}